Clinical Trials Logo

Clinical Trial Summary

Primary Sjögren's syndrome (pSS) can affect various organs, sometimes leads to life-threatening conditions and is always responsible for a decreased quality of life. Its evolution is chronic, with flares and relapses, and the need for reliable biomarkers to be carried out routinely is major in patients' follow-up. Because of the existence of autoreactive immunoglobulins E (IgE) in autoimmune diseases, the recently described role for anti-Ro/SSA antibodies in inducing interferon alpha (IFNα) signaling and the specific pharmacologic properties of IgE, anti-Ro/SSA IgE should be an interesting biomarker to determine pSS's activity. The aim of the study is to evaluate whether the proportion of anti-Ro/SSA IgE positive patients is higher in patients with active disease (i.e. Eular Sjögren Syndrome Disease Activity Index≥ 5). All consecutive patients with pSS (new or already known diagnosis) will be included, Anti-Ro/SSA IgE titers will be determined, the disease's features will be collected (including Eular Sjögren Syndrome Disease Activity Index/Eular Sjogren's Syndrome Patient Reported Index).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03003572
Study type Observational
Source Centre Hospitalier Universitaire de Saint Etienne
Contact Pascal CATHEBRAS, MD PhD
Phone (0)477828342
Email [email protected]
Status Recruiting
Phase
Start date March 27, 2018
Completion date June 2027

See also
  Status Clinical Trial Phase
Recruiting NCT03040583 - The ASSESS National Multi-center Prospective Cohort
Completed NCT01989819 - Primary Sjögren Syndrome
Completed NCT02291029 - Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome Phase 2
Terminated NCT02610543 - UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome Phase 2
Recruiting NCT04212572 - Ultrasound Abnormalities of the Salivary Glands in Primary Sjögren's Syndrome According to the Duration of the Disease
Completed NCT02149420 - PD of VAY736 in Patients With Primary Sjögren's Syndrome Phase 2
Not yet recruiting NCT04858464 - Reliability, Validity of the Turkish Version of the Primary Sjögren Syndrome Quality of Life (PSS-QoL) Questionnaire
Completed NCT00632866 - Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome Phase 3
Completed NCT02334306 - A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome Phase 2
Active, not recruiting NCT04078386 - A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome Phase 2
Not yet recruiting NCT04605978 - Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients Phase 2
Completed NCT02775916 - Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome Phase 2
Completed NCT02464319 - A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome Phase 2
Not yet recruiting NCT04981145 - The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome Phase 4
Terminated NCT01552681 - Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome Phase 2
Recruiting NCT04186871 - Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis Phase 2
Completed NCT00426543 - Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome Phase 2
Completed NCT03627065 - A Study of INCB050465 in Primary Sjögren's Syndrome Phase 2
Recruiting NCT04684654 - BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome Phase 1
Withdrawn NCT02495129 - Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome Phase 1/Phase 2